Ipsen (OTCMKTS:IPSEY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The firm presently has a $25.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 12.41% from the stock’s current price.
According to Zacks, “Ipsen S.A. is a pharmaceutical company. It provide drugs for urology, oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology and cardiovascular. Ipsen S.A. is headquartered in Boulogne-Billancourt, France. “
Several other analysts have also weighed in on IPSEY. Barclays raised Ipsen from an “equal weight” rating to an “overweight” rating in a report on Monday, October 26th. Bank of America lowered Ipsen from a “buy” rating to a “neutral” rating in a report on Friday, December 4th. Morgan Stanley lowered Ipsen from an “overweight” rating to an “equal weight” rating in a report on Tuesday, December 8th. Societe Generale raised Ipsen from a “hold” rating to a “buy” rating in a report on Thursday, January 14th. Finally, Bryan, Garnier & Co lowered Ipsen from a “buy” rating to a “neutral” rating in a report on Wednesday, December 2nd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ipsen presently has a consensus rating of “Buy” and an average target price of $25.00.
Ipsen SA operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology.
See Also: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.